Virtu Financial LLC Cuts Stake in Altimmune, Inc. (NASDAQ:ALT)

Virtu Financial LLC lessened its holdings in Altimmune, Inc. (NASDAQ:ALT) by 20.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,831 shares of the company’s stock after selling 22,928 shares during the quarter. Virtu Financial LLC owned 0.12% of Altimmune worth $626,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Bellevue Group AG boosted its stake in shares of Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after purchasing an additional 263,660 shares during the period. Barclays PLC boosted its position in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the period. Geode Capital Management LLC boosted its position in Altimmune by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the period. FMR LLC grew its holdings in Altimmune by 546.8% in the 3rd quarter. FMR LLC now owns 51,060 shares of the company’s stock worth $314,000 after acquiring an additional 43,166 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Altimmune by 27.5% in the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after acquiring an additional 42,553 shares during the period. 78.05% of the stock is owned by institutional investors.

Altimmune Stock Performance

Shares of NASDAQ:ALT opened at $5.89 on Wednesday. The stock has a 50 day moving average price of $6.31 and a 200-day moving average price of $7.08. The firm has a market capitalization of $453.61 million, a P/E ratio of -3.80 and a beta of 0.87. Altimmune, Inc. has a 52-week low of $5.14 and a 52-week high of $11.16.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. On average, equities analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on ALT shares. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Tuesday, March 18th. Finally, Stifel Nicolaus assumed coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Insider Buying and Selling at Altimmune

In related news, CFO Gregory L. Weaver bought 10,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.